A retrospective investigation of the relationship between neuroblastoma response to anti‐GD2 monoclonal antibodies and exposure to opioids for pain management

Autor: Kyle J. Morgan, Andrew Dudas, Wayne L. Furman, M. Beth McCarville, Barry L. Shulkin, Zhaohua Lu, Himani Darji, Doralina L. Anghelescu
Rok vydání: 2022
Předmět:
Zdroj: Pediatric Blood & Cancer. 70
ISSN: 1545-5017
1545-5009
DOI: 10.1002/pbc.30069
Popis: Recent increased awareness and research studies reflect possible associations between opioid exposure and cancer outcomes. Children with neuroblastoma (NB) often require opioid treatment for pain. However, associations between tumor response to chemotherapy and opioid exposure have not been investigated in clinical settings.This is a single-institution retrospective review of patients with NB treated between 2013 and 2016. We evaluated opioid consumption quantified in morphine equivalent doses (mg/kg) based on nurse- or patient-controlled analgesia during antibody infusions. We also analyzed their associations with change in primary tumor volume and total tumor burden.Of 42 patients given opioids for pain related to anti-disialoganglioside monoclonal antibodies (anti-GD2 mAb), data completion was achieved for 36, and details of statistical analyses were entered. Median total weight-based morphine equivalent (over 8 days) was 4.71 mg/kg (interquartile range 3.49-7.96). We found a statistically insignificant weak negative relationship between total weight-based morphine equivalents and tumor volume ratio (correlation coefficient -.0103, p-value .9525) and a statistically insignificant weak positive relationship between total weight-based morphine equivalent and Curie score ratio (correlation coefficient .1096, p-value .5247).Our study found no statistically significant correlation between opioid consumption and natural killer (NK) cell-mediated killing of NB cells as measured by effects on tumor volume/tumor load.
Databáze: OpenAIRE
Externí odkaz: